How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Making Agricultural Products Locally Essential (MAPLE) Act
Client: AMRYT PHARMA · Firm: AMRYT PHARMA
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2023 · first_quarter · 1T
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Q4
Source: Senate LDA
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Q3
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Q2
The FDA user fee reauthorization, and issues related to rare disease innovation including the HEART ACT (HR 7667) and the BENEFIT Act (HR4472).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · RR
Patient access to medicines, Innovation (FDA), Pricing and Reimbursement